EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry

Cornelia Voigt-Müller, Michelle Pfaffenlehner, Günther Bernert, Hakan Cetin iD, Tim Hagenacker, Heike Kölbel, Hanns Lochmüller, Christian Pfeuffer, Katharina Vill, Maggie C Walter, Janbernd Kirschner iD, Astrid Pechmann iD und 1 weitere

Brain · 2026

DOI: 10.1093/brain/awaf472 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Brain, 2026. Verfasst von Cornelia Voigt-Müller und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropediatrics and Muscle Disorders, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg D-79…. Hauptthemen laut MEDLINE: Oligonucleotides, Muscular Atrophy, Spinal, Biological Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Real-world treatments for 5q-spinal muscular atrophy (SMA) have evolved rapidly following the sequential approval of three disease-modifying treatments (DMTs): nusinersen, onasemnogene abeparvovec and risdiplam. The aim of this study was to map the sequence and timing of SMA treatments accurately using the SMArtCARE registry, a disease-specific registry for patients with SMA across 84 participating centres in Germany, Austria and Switzerland. All patients registered in SMArtCARE were included in the analysis. Patients were grouped based on their treatment regimen: those who remained on the first DMT versus those who switched DMT. The impacts of clinical and genetic factors on treatment decisions were evaluated, including age at initiation of treatment, SMN2 copy number, motor function status, the need for ventilator support or tube feeding, and the presence of scoliosis. A total of 2140 patients were included. Of these, 1294 patients (60.5%) initiated treatment with nusinersen, 514 patients (24.0%) with risdiplam and 243 patients (11.4%) with onasemnogene abeparvovec. Overall, 1366 patients (63.8%) remained on the first DMT. Most treatment switches occurred shortly after approval of a new DMT. Notably, most patients who switched showed no change in motor milestone status between the start of the first and the second DMT. In this large real-world cohort, we present the first comprehensive analysis of SMA treatment patterns across all age groups and disease severities. Although most patients remained on the first DMT, switches were observed, mainly after DMT approvals. Decisions to switch appear multifactorial and are not related directly to motor function effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligonucleotidesMuscular Atrophy, SpinalBiological ProductsHumansRegistriesMaleFemaleChild, PreschoolInfantChildAdolescentGermanyAustriaTreatment OutcomeAzo CompoundsPyrimidines

Stichwörter der Autor:innen

DMTSMAdisease-modifying treatmentspinal muscular atrophy

Substanzen

nusinersenOligonucleotidesRisdiplamBiological ProductsAzo CompoundsPyrimidines

Autor:innen und Institutionen

  • Department of Neuropediatrics and Muscle Disorders, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg D-79106, Germany.
  • Freiburg Center for Data Analysis and Modeling and AI, University of Freiburg, Freiburg D-70104, Germany.
  • Faculty of Medicine and Medical Center-University of Freiburg, Institute of Medical Biometry and Statistics, Freiburg D-79104, Germany.
  • Neuromuscular Research Division, Department of Paediatrics and Adolescent Medicine, University Hospital Vienna, Vienna A-1090, Austria.
  • Department of Neurology, Medical University of Vienna, Vienna A-1090, Austria.
  • Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna A-1090, Austria.

ORCID-Profile: Hakan Cetin, Janbernd Kirschner, Astrid Pechmann

Zitieren

APA

Voigt-Müller, C., Pfaffenlehner, M., Bernert, G., Cetin, H., Hagenacker, T., Kölbel, H., Lochmüller, H., Pfeuffer, C., Vill, K., Walter, M. C., Kirschner, J., Pechmann, A., & SMArtCARE study group (2026). Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry. Brain. https://doi.org/10.1093/brain/awaf472

Vancouver

Voigt-Müller C, Pfaffenlehner M, Bernert G, Cetin H, Hagenacker T, Kölbel H, et al. Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry. Brain. 2026. doi:10.1093/brain/awaf472

BibTeX
@article{VoigtMller2026,
  author = {Voigt-Müller, Cornelia and Pfaffenlehner, Michelle and Bernert, Günther and Cetin, Hakan and Hagenacker, Tim and Kölbel, Heike and Lochmüller, Hanns and Pfeuffer, Christian and Vill, Katharina and Walter, Maggie C and Kirschner, Janbernd and Pechmann, Astrid and SMArtCARE study group, SMArtCARE study group},
  title = {Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry},
  journal = {Brain},
  year = {2026},
  doi = {10.1093/brain/awaf472}
}
Kostenlos starten →